The International Cannabis Business Conference team has received confirmation that Slovenia's Parliament has officially introduced a medical cannabis policy modernization measure that, once adopted, will make Slovenia home to Europe's most progressive medical cannabis model.
Full legalization for medical and scientific use
The bill legalizes the cultivation, production, distribution, and use of Cannabis sativa L. for medical and scientific purposes, under a regulated and controlled system.
Open licensing system
The bill introduces a non-restrictive licensing system: any individual or company that fulfills the conditions can obtain a license. There will be no public tender and no state monopoly. Both public and private entities can produce and distribute medical cannabis.
Strict quality and production standards
All cannabis for medical use must be grown and processed according to GACP (Good Agricultural and Collection Practice), GMP (Good Manufacturing Practice), and European Pharmacopoeia standards, ensuring high-quality, safe products for patients.
Cannabis and THC removed from prohibited drugs list for medical and scientific purposes
Cannabis (plant, resin, extracts) and THC will be removed from Slovenia's list of prohibited substances within the regulated medical and scientific framework.
Standard prescription process
Medical cannabis will be available on regular medical (MD and DMD) or veterinary prescriptions, like other medications. Special narcotic prescription protocols will no longer be required.
Ensured patient access
The law ensures a stable and continuous supply of cannabis through pharmacies, licensed wholesalers, and healthcare providers, so that patients are not dependent on imports or irregular access.
The law follows the results of the 2024 advisory referendum, where 66.7% of voters supported medical cannabis cultivation. It received majority support in every voting district, indicating strong public backing.
Slovenia's medical cannabis market is projected to grow by 4% annually, reaching over €55 million by 2029. The bill opens the sector to domestic innovation, job creation, and export potential.
The bill is aligned with UN drug conventions and builds on successful models from countries like Germany, the Netherlands, Austria, and the Czech Republic, ensuring legal sufficiency and international compatibility.
Source: ICBC